Patents Assigned to ImmunoCellular Therapeutics, Ltd.
  • Patent number: 10137182
    Abstract: Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: November 27, 2018
    Assignee: Immunocellular Therapeutics, Ltd.
    Inventors: James G. Bender, John S. Yu
  • Patent number: 8604167
    Abstract: An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 10, 2013
    Assignee: ImmunoCellular Therapeutics, Ltd.
    Inventors: Manish Singh, James Bender
  • Publication number: 20130115279
    Abstract: An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.
    Type: Application
    Filed: January 9, 2013
    Publication date: May 9, 2013
    Applicant: IMMUNOCELLULAR THERAPEUTICS, LTD.
    Inventor: IMMUNOCELLULAR THERAPEUTICS, LTD.
  • Patent number: 8383768
    Abstract: An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: February 26, 2013
    Assignee: ImmunoCellular Therapeutics, Ltd.
    Inventors: Manish Singh, James Bender
  • Patent number: 7691376
    Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: April 6, 2010
    Assignee: ImmunoCellular Therapeutics, Ltd.
    Inventor: Cohava Gelber
  • Patent number: 7687607
    Abstract: The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 30, 2010
    Assignee: ImmunoCellular Therapeutics, Ltd.
    Inventor: Cohava Gelber
  • Patent number: 7498129
    Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies, and antibody binding fragments thereof, capable of being used for therapeutic, diagnostic, detection and cell purification purposes. An exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to surface antigen expressed on multiple myeloma cells and on ovarian cancer cells.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: March 3, 2009
    Assignee: ImmunoCellular Therapeutics, Ltd.
    Inventor: Cohava Gelber
  • Patent number: 7435554
    Abstract: The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: October 14, 2008
    Assignee: ImmunoCellular Therapeutics, Ltd.
    Inventor: Cohava Gelber
  • Patent number: 7435415
    Abstract: The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: October 14, 2008
    Assignee: ImmunoCellular Therapeutics, Ltd.
    Inventor: Cohava Gelber